Drug Trial Radar · NCT02145182
Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)
Last checked: Nov 20, 2026Latest source record: Dec 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
288
Actual
Start
Aug 21, 2014
Primary completion
Nov 22, 2016
Study completion Nov 22, 2016
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- CTI Clinical Trial and Consulting Services
- First posted
- May 22, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine if eculizumab is safe and could be used to prevent delayed graft function (DGF) following kidney transplantation.
Conditions
- Delayed Graft Function
Interventions
EculizumabDrug
Eculizumab is a complement component 5 inhibitor.
PlaceboDrug
0.9% sodium chloride
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Of Participants With Delayed Graft Function (DGF) In The First Seven Days Post-transplantTime frame: First 7 days post transplantation
Locations
78 sites in 9 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Phoenix, Arizona
Site not named
Los Angeles, California
Site not named
Palo Alto, California
Site not named
San Francisco, California
Site not named
San Francisco, California
Site not named
Aurora, Colorado
Site not named
New Haven, Connecticut
Site not named
Washington D.C., District of Columbia
Site not named
Tampa, Florida
Site not named
Augusta, Georgia
Site not named
Chicago, Illinois
Site not named
Lexington, Kentucky
Site not named
New Orleans, Louisiana
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Detroit, Michigan
Site not named
Minneapolis, Minnesota
Site not named
St Louis, Missouri
Site not named
Livingston, New Jersey
Site not named
New York, New York
Site not named
New York, New York
Site not named
The Bronx, New York
Site not named
Chapel Hill, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Charleston, South Carolina
Site not named
Fort Worth, Texas
Site not named
Houston, Texas
Site not named
Charlottesville, Virginia
Site not named
Richmond, Virginia
Site not named
Seattle, Washington
Site not named
Camperdown, New South Wales, Australia
Site not named
Westmead, New South Wales, Australia
Site not named
Adelaide, South Australia, Australia
Site not named
Clayton, Victoria, Australia
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
São Paulo, Brazil
Site not named
Vancouver, British Columbia, Canada
Site not named
Halifax, Nova Scotia, Canada
Site not named
Toronto, Ontario, Canada
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.